SHR2554 to maintain remission in peripheral T-cell lymphoma
Treatments studied
Part of Cancer clinical trials.
This study tests the drug SHR2554 as a maintenance therapy for people with peripheral T-cell lymphoma who responded well to their first chemotherapy. The goal is to help keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have a type of peripheral T-cell lymphoma (like PTCL, ALCL, or ENKTL), but not cutaneous T-cell lymphoma.
- You have finished your first round of chemotherapy and it worked well (complete or partial remission).
- You are generally able to do daily activities (ECOG score 0, 1, or 2).
- You have not had another cancer in the last 3 years that is not cured.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This clinical trial tests a new combination of two drugs (SHR2554 and liposomal mitoxantrone) as a first treatment for adults with certain types of peripheral T-cell lymphoma. The goal is to see if this combination is safe and effective.
This trial tests an experimental drug called TR115 versus your doctor's choice of standard treatment for peripheral T-cell lymphoma that has come back or stopped responding to prior treatments. TR115 may help control this rare blood cancer by targeting specific cancer pathways.
This trial tests a combination of three medicines (anti-PD-1, lenalidomide, and azacitidine) for adults with relapsed or refractory peripheral T-cell lymphoma (PTCL) that is measurable or growing. It aims to shrink lymphoma and improve control of the disease when standard treatments haven’t worked or have stopped working.
This trial tests a new drug called SHR2554 (compared to chidamide) for T-cell lymphoma that has not responded to or come back after prior treatment. It's a Phase 3 study to see if the drug can help control the cancer.
This trial tests a combination of two drugs (adebrelimab and SHR2554) for patients with T-cell or NK/T-cell lymphomas that have stopped responding to previous treatments. The goal is to see if this combination can shrink tumors and help patients live longer.
This study tests two new drugs (SHR-0302 and SHR-2554) for people with a type of lymphoma (peripheral T-cell lymphoma) that has come back or not responded to prior treatment. The goal is to see if the combination can help control the cancer.
Hear when a new PTCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.